[Stimulating and protective effect of recombinant interleukin-1-beta (beta-leukin) on leukopoiesis in chemotherapy of malignant tumors].
Clinical studies were carried out in a group of 71 cancer patients to evaluate the effects of intravenous infusion of human recombinant interleukin-1-beta (betaleukin) (I and II phases). It was shown that daily single doses of 10-20 ng/kg body, for 5 days, markedly stimulated leukopoiesis (granulocytopoiesis) in toxic (grade II-IV) leukopenia which hampered combination chemotherapy. A protective effect on leukopoiesis (granulocy-topoiesis) was recorded in cases of moderate leukopenia when chemotherapy was continued. Such side-effects as stage I-III hyperthermia (13.5%) or their combination (50.0%) were effectively managed with paracetamol and antihistamines administration without causing suspension of the drug.
Gershanovich
M L
ML
Ketlinskiĭ
S A
SA
Filatova
L V
LV
Danova
L A
LA
Korolenko
V O
VO
Simbirtsev
A S
AS
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006098:Granulocytes / Q000187:drug effects*; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control*; D008214:Lymphocytes / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy*; D016896:Treatment Outcome
D007375:Interleukin-1; D011994:Recombinant Proteins